In summary, these results suggest that MG‐derived VDBP mainly targets the megalin receptor of inhibitory neurons, thereby initiating the downstream SRC pathway and leading to neuronal synaptic damage, ultimately participating in the development of depression. Here, SRC is linked to depressive symptom measurement.